Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SCN4A | P35499 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL461337 | 0.84 | THRB (0.40) | HDAC4THRBTDP1KDM4EPKM | |
| SCHEMBL29701281 | 0.83 | KDM4E (0.34) | HDAC4THRBTDP1KDM4EPKM | |
| SCHEMBL10586576 | 0.83 | KDM4E (0.34) | HDAC4THRBTDP1KDM4EPKM | |
| SCHEMBL9440141 | 0.79 | LMNA (0.34) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL7109806 | 0.79 | MAPT (0.39) | LMNATSHRKMT2AHDAC4KDM4E | |
| SCHEMBL7031865 | 0.77 | KMT2A (0.35) | LMNATSHRMAPK1SCN4ASCN5A | |
| SCHEMBL387970 | 0.76 | L3MBTL1 (0.35) | TSHRMAPK1THRBTDP1KDM4E | |
| SCHEMBL8660719 | 0.76 | MEN1 (0.40) | LMNATSHRKMT2AHDAC4TDP1 | |
| SCHEMBL10415346 | 0.75 | TSHR (0.35) | TSHRKDM4E | |
| SCHEMBL8611475 | 0.74 | KIF11 (0.33) | LMNATSHRMAPK1SCN4ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7112594-B2 | Fused bicyclic amide compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-09-26 | — | — | US | disclosed |
| US-20030203909-A1 | Fused bicyclic amide compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2003-10-30 | — | — | US | disclosed |
| EP-1310488-A1 | FUSED BICYCLIC AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-05-14 | — | — | EP | disclosed |
| EP-0207474-B1 | SILVER HALIDE PHOTOGRAPHIC MATERIAL | KONICA CORPORATION (JP) | 1990-08-29 | — | — | EP | disclosed |
| US-4792515-A | COATING OF POLYVINYL ACETATE AND PARAFFIN WAX OR OXIDIZED POLYTHYLENE WITH DIAZOTYPE DISPERSION ZONE | ANDREWS PAPER & CHEMICAL CO., INC. (US) | 1988-12-20 | — | — | US | disclosed |
| US-4766060-A | 1-HYDROXY-2-AMIDO-4-PHENYLOXY NAPHTHALENE CYAN COUPLER | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1988-08-23 | — | — | US | disclosed |
| EP-0277273-A1 | Diazotype compositions | Andrews Paper and Chemical Co., Inc. (US) | 1988-08-10 | — | — | EP | disclosed |
| EP-0207474-A2 | Silver halide photographic material | KONICA CORPORATION (JP) | 1987-01-07 | — | — | EP | disclosed |
| US-4478926-A | STABILIZERS | ANDREWS PAPER & CHEMICAL CO., INC. (US) | 1984-10-23 | — | — | US | disclosed |
| US-4430420-A | USING AN AMINOSULFONYLHYDRAZONE REDUCING AGENT | EASTMAN KODAK COMPANY (US) | 1984-02-07 | — | — | US | disclosed |
| US-4426441-A | PHOTOTHERMOGRAPHY | EASTMAN KODAK COMPANY (US) | 1984-01-17 | — | — | US | disclosed |
| US-4403028-A | HEAT RESISTANT, NONFLAMMABLE | ANDREWS PAPER & CHEMICAL CO., INC. (US) | 1983-09-06 | — | — | US | disclosed |
| US-4401744-A | Diazotype compositions with improved printing performance | ANDREWS PAPER & CHEMICAL CO., INC. (US) | 1983-08-30 | — | — | US | disclosed |
| US-4343884-A | Diazotype developing process and acidic developer with amine base salt | ANDREWS PAPER & CHEMICAL CO., INC. (US) | 1982-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203909-A1 | Fused bicyclic amide compounds and medicinal use thereof | BET1, NFATC1, ARG1 | LMNA 3072/4885TSHR 994/4885MAPK1 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.